Description General description A cell-permeable fluorinated N,N-dialkylaminostilbene (FIDAS) compound that inhibits MAT2A-catalyzed SAM (S-adenosylmethionine) synthesis (IC50 =4.9 µM; [L-Met] = [ATP] = 1 mM, [MAT2A] = 10 µg/mL; 20 min preincubation prior to 30 min reaction) by targeting SAM-binding pocket at the MAT2A dimer interface. Shown to downregulate intracellular SAM level (by 64%; 36 h;10 µM) and Wnt signaling in LS174 CRC (colorectal cancer) cultures and is at least 10-fold more potent than its analogs Pterostilbene (Cat. No. 523310) and Resveratrol (Cat. No. 554325) in inhibiting LS174 proliferation both in vitro (by 70%, 85%, and 90% in 4 d, respectively, with 0.1, 0.3, and 1 µM inhibitor) and in mice in vivo (by 75% on d26; 20 mg/kg/day; i.p.). A cell-permeable fluorinated N,N-dialkylaminostilbene (FIDAS) compound that inhibits MAT2A-catalyzed SAM (S-adenosylmethionine) synthesis by targeting SAM-binding pocket at the MAT2A dimer interface. Shown to downregulate intracellular SAM level (by 64%; 36 h;10 µM) and Wnt signaling in LS174 colorectal cancer cultures and is at least 10-fold more potent than Pterostilbene (Cat. No. 523310) and Resveratrol (Cat. No. 554325) in inhibiting LS174 proliferation both in vitro (by 90% in 4 d; 1 µM) and in mice in vivo (by 75% on d26; 20 mg/kg/day; i.p.). Packaging 10 mg in Glass bottle Packaged under inert gas Warning Toxicity: Regulatory Review (Z) Other Notes Zhang, W., et al. 2013. ACS Chem.Biol.18, In press. Zhang, W., et al. 2011. J. Med. Chem.54, 7579.